avapro has been researched along with Cerebral Hemorrhage in 2 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 9.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 5.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, M | 1 |
| Kamal, AK | 1 |
| Healey, JS | 1 |
| Hart, RG | 1 |
| Pogue, J | 1 |
| Pfeffer, MA | 1 |
| Hohnloser, SH | 1 |
| De Caterina, R | 1 |
| Flaker, G | 1 |
| Yusuf, S | 1 |
| Connolly, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for avapro and Cerebral Hemorrhage
| Article | Year |
|---|---|
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny | 2008 |
1 other study available for avapro and Cerebral Hemorrhage
| Article | Year |
|---|---|
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |